Redx Pharma

CompanyUnited KingdomFounded 2010

Redx Pharma develops 2 assets, the furthest in phase 2 (Zelasudil in fibrosis). Mostly small molecule acting on ROCK2, inflammation and MAP4K4; based in the United Kingdom, founded in 2010.

2
Assets
Furthest: Phase 2; 4
Trials: 0
Signals

Pipeline

2

Zelasudil
Selective ROCK2 inhibitor
Phase 2, Small molecule, Inflammation, ROCK2, fibrosis, idiopathic pulmonary fibrosis
RXC008
Gastrointestinal-restricted pan-ROCK inhibitor
Phase 1, Small molecule, ROCK1, ROCK2, fibrostenotic Crohn's disease

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms2
Trials4
Similar companies6

Updated 8 Oct 2026 · 11 sources